Jeay, Sébastien

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell

Acute Lymphoblastic Leukemia researchAcute Myeloid Leukemia Research

Cited by 295

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysCancer Mechanisms and Therapy

Cited by 203

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Jeay, S., Ferretti, S., Holzer, P., Fuchs, J., Chapeau, E. A., Wartmann, M., Sterker, D., Romanet, V., Murakami, M., Kerr, G., et al. (2018) · Cancer Research

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 87

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 85

The public repository of xenografts enables discovery and randomized phase II-like trials in mice

Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell

Acute Lymphoblastic Leukemia researchAcute Myeloid Leukemia Research

Cited by 80

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Furet, P., Masuya, K., Kallen, J., Stachyra-Valat, T., Ruetz, S., Guagnano, V., Holzer, P., Mah, R., Stutz, S., Vaupel, A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters

Cancer-related Molecular PathwaysComputational Drug Discovery Methods

Cited by 80

Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced TP53 wt acute leukemias

Stein, E., Chromik, J., DeAngelo, D. J., Chatterjee, M., Noppeney, R., Vos, F. D., Minami, H., Jeay, S., Meille, C., Halilovic, E., et al. (2017) · Cancer Research

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 11